Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Alotaibi, Shaykhah
  • Niederwieser, Dietger
  • Ahmed, Syed Osman
  • Mohty, Mohamad
  • Aljurf, Mahmoud

Grupos

Abstract

Acute myeloid leukemia (AML) treatment landscape had evolved over the last decades with better understanding of the disease genomics and the use of the targeted therapy, despite this treatment evolution, 7 + 3 remains the mainstay treatment for most AML cases. Many attempts had been made to improve the treatment outcome with 7 + 3 like manipulating the doses or the duration, but with no significant change in the outcome. In 2017 FDA approved CPX-351,a liposomal formulation of cytarabine and daunorubicin at a fixed 5:1 molar ratio, for the treatment of adults with newly diagnosed AML with myelodysplasia-related changes and therapy-related AML (t-AML). Since the approval, many trials were conducted or still ongoing in assessing the role of CPX-351 in treating different patient populations, AML subcategories or when combined with different agents. In this review, we will summarize the current role of CPX-351 in treating this largely heterogeneous disease.

Copyright © 2022. Published by Elsevier Inc.

Datos de la publicación

ISSN/ISSNe:
2152-2650, 2152-2669

Clinical Lymphoma Myeloma & Leukemia  CIG MEDIA GROUP, LP

Tipo:
Article
Páginas:
575-580
PubMed:
35418351
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,778 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 7

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Acute Myeloid Leukemia; CPX -351; Induction Chemotherapy; Myelodysplastic Syndromes

Campos de Estudio

Cita

Compartir